Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Different resistance mechanisms, especially, T790M secondary acquired point mutation and in some cases amplification of cMET, have been a major setback for the lung cancer therapies.
|
28362115 |
2017 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
|
27270313 |
2016 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Notably, the patient with EGFR-T790M germline mutation had multiple maternal family members diagnosed with lung cancers, strongly supporting its role in inherited lung cancer.
|
30610926 |
2019 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
<i>In silico</i> insight into EGFR treatment in patients with lung carcinoma and T790M mutations.
|
28565760 |
2017 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Its clinical utility has been well demonstrated for EGFR T790M testing in lung cancer patients suffering progress after tyrosine kinase inhibitor treatment.
|
31620244 |
2019 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
First-generation EGFR TKI exposure did not influence the prevalence of T790M in lung cancer acquired resistance to afatinib.
|
26862733 |
2016 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
It will be clinically valuable to investigate the involvement of HGF-MET-mediated signaling in de novo and acquired resistance to irreversible EGFR-TKIs in lung cancer harboring T790M mutation in EGFR.
|
20008840 |
2010 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Brief Report on the Detection of the EGFR T790M Mutation in Exhaled Breath Condensate from Lung Cancer Patients.
|
29751135 |
2018 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Gefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein Noxa.
|
23185274 |
2012 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study aims to develop new nanoformulations of EGFR T790M targeted inhibitor AZD9291 and paclitaxel (PTX) for combination therapy of lung cancer.
|
29874151 |
2018 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The three major clinically relevant mechanisms of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant lung cancer are a second mutation in the EGFR gene (T790M), Met amplification, and increased expression of hepatocyte growth factor (HGF).
|
22592212 |
2012 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
We developed experimental brain metastasis models by intraventricular injection (intraventricular injection mouse model; IVM) of HER2-positive breast cancer (MDA-MB-361-luc-BR2/BR3) or T790M-EGFR-positive lung cancer (NCI-H1975-luc) cells.
|
29321587 |
2018 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.
|
25074459 |
2014 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although afatinib inhibited the growth of lung cancer cells with low T790M allele frequencies in preclinical studies, this could not be translated into clinical efficacy in terms of lowering the rate or delaying the time of T790M acquisition.
|
31030101 |
2019 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Non-small-cell lung cancer (NSCLC) represents 85% of lung cancer in elderly patients.In the present study performed in the 36 elderly subjects with epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC, osimertinib 80 mg demonstrated statistically significant improvement in the objective response rate, which was comparable to those in the nonelderly population.Osimertinib appears to be an effective and safe treatment option in elderly patients with advanced NSCLC with EGFR mutation; further research in larger scale is warranted.
|
30651400 |
2019 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
|
24453288 |
2014 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
High-level HGF expression was detected more frequently than EGFR T790M secondary mutation or MET amplification in tumors with intrinsic and acquired EGFR-TKI resistance in EGFR mutant lung cancer in Japanese patients.
|
22052230 |
2011 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Loss of EPHA2 reduced the viability of erlotinib-resistant tumor cells harboring EGFR(T790M) mutations in vitro and inhibited tumor growth and progression in an inducible EGFR(L858R+T790M)-mutant lung cancer model in vivo.
|
26744526 |
2016 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Osimertinib-a third-generation EGFR-TKI-targets the T790M mutation and has demonstrated high efficacy against <i>EGFR</i>-mutated lung cancer.
|
30445769 |
2018 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
T790M mutant copy number quantified via ddPCR predicts outcome after osimertinib treatment in lung cancer.
|
29963252 |
2018 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
OBX1-012 treatment was highly effective against human EGFR-mutant lung cancer models with or without EGFR T790M, not only in vitro but also in vivo.
|
29754184 |
2018 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Evidence-based best practices for <i>EGFR</i> T790M testing in lung cancer in Canada.
|
29719432 |
2018 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
A preexisting EGFR T790M mutation was noted in 25% of patients with EGFR-mutant lung cancer.
|
24737599 |
2014 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our findings suggest that radiotherapy combined HS-10182 is a novel treatment for lung cancer cells which have acquired the T790M mutation.
|
29545967 |
2018 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The clinical features of EGFR T790M-mutant lung cancer were similar to those of sensitive EGFR-mutant lung cancer, except for the overrepresentation of never-smokers and brain metastasis.
|
25450875 |
2015 |